This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary objectives: The escalation portion of the study will determine the maximum tolerated dose (MTD) of G3139/ Cisplatin, and will help determine the toxicities of this combination. Primary endpoints of the phase II portion of the study will be response rate, time to progression, and median survival. Secondary objectives will be the collection of additional toxicity data for this combination. In patients who consent to biopsies the investigators will aim to determine the expression of a number of molecular markers and targets of G3139.
Showing the most recent 10 out of 370 publications